Virus-induced senescence is a driver and therapeutic target in COVID-19

Soyoung Lee, Yong Yu, Jakob Trimpert, Fahad Benthani, Mario Mairhofer, Paulina Richter‐Pechańska, Emanuel Wyler, Dimitri Belenki, Sabine Kaltenbrunner, Maria Pammer, Lea Kausche, Theresa C. Firsching, Kristina Dietert, Michael Schotsaert, Carles Martínez‐Romero, Gagandeep Singh, Séverine Kunz, Daniela Niemeyer, R Ghanem, Helmut J.f. Salzer, Christian Paar, Michael Mülleder, Melissa B. Uccellini, Edward Michaelis, Amjad Khan, Andrea Lau, Martin Schönlein, Anna Habringer, Josef Tomasits, Julia M. Adler, Susanne Kimeswenger, Achim D. Gruber, Wolfram Hoetzenecker, Herta Steinkellner, Bettina Purfürst, Reinhard Motz, Francesco Di Pierro, Bernd Lamprecht, Nikolaus Osterrieder, Markus Landthaler, Christian Drosten, Adolfo Garcı́a-Sastre, Rupert Langer, Markus Ralser, Roland Eils, Maurice Reimann, Dorothy Ngo-Yin Fan, Clemens A. SchmittNature 2021 · DOI

Abstract

Severe COVID-19 is characterized by a "cytokine storm" and multi-organ failure, often persisting after viral clearance. This study identifies virus-induced senescence (VIS) as a critical driver of this pathology. SARS-CoV-2 infection triggers a senescent state in host cells, characterized by the secretion of pro-inflammatory and pro-coagulatory factors (SASP). Eliminating these "zombie" cells using senolytic drugs reduces systemic inflammation and improves survival in animal models, suggesting a novel therapeutic avenue for severe COVID-19 and potentially other viral diseases.

Introduction

While vaccines and antivirals have mitigated the impact of COVID-19, severe cases continue to pose a significant clinical challenge. These cases are often defined by a hyper-inflammatory response—a cytokine storm—leading to acute respiratory distress syndrome (ARDS), thrombosis, and multi-organ failure. The biological mechanism that transitions a standard viral infection into this catastrophic systemic collapse has remained elusive. This research investigates cellular senescence—a state of permanent cell cycle arrest with high secretory activity—as the potential link between viral infection and systemic pathology.

Methods

The study utilized a multi-scale approach combining in vitro cell biology, animal models, and human clinical data:

  • Cellular Models: Human fibroblasts and lung epithelial cells were infected with SARS-CoV-2 and other viruses (VSV, Lentivirus) to characterize VIS using markers such as SA-β-gal staining, p16INK4A expression, and SASP profiling.
  • Animal Models: Therapeutic efficacy was tested in Syrian golden hamsters, Roborovski dwarf hamsters (highly susceptible), and K18-hACE2 transgenic mice.
  • Senolytics: The study evaluated compounds that selectively eliminate senescent cells, including navitoclax (a BCL-2 inhibitor) and a combination of dasatinib and quercetin (D/Q).
  • Human Data: Analysis included COVID-19 autopsy lung tissue and re-evaluation of clinical trial data involving quercetin.

Key Insights: VIS as a Universal Response and Pathogenic Driver

A central finding is that VIS is a universal host response to viral insult, not limited to SARS-CoV-2. Various viruses trigger this state via the cGAS–STING pathway, a cytoplasmic DNA sensing mechanism.

Figure 1: VIS is induced by a wide range of viruses, including AAV, Lentivirus, HCoV-NL63, and VSV, across multiple cell lines (RPE1, A549, HNEpC).

VIS cells act as "zombie" cells, secreting a potent cocktail of factors known as the Senescence-Associated Secretory Phenotype (SASP). This secretome induces "secondary" senescence in neighboring healthy cells, such as endothelial cells and macrophages, amplifying the inflammatory signal. Crucially, the VIS secretome is enriched with pro-coagulatory factors like PAI-1, providing a direct link between viral infection and the micro-thrombosis observed in severe COVID-19.

Key Results: Therapeutic Potential of Senolytics

The researchers demonstrated that targeting VIS cells can significantly alter disease outcomes. In the lethal Roborovski hamster model, 100% of animals treated with D/Q survived, compared to high mortality in the control group. Senolytic treatment reduced markers of senescence in the lungs and mitigated pneumonia and endothelialitis.

Figure 2: SARS-CoV-2 induces senescence markers (SA-β-gal) and SASP factors (IL-6, IL-8, MMP3), which are significantly reduced by p53 knockdown (shp53) or senolytic treatment (GS).

Quantitative analysis showed that VIS cells massively upregulate pro-inflammatory cytokines like IL-6 and IL-8. Senolytic intervention blunted these levels in animal models. Furthermore, re-analysis of human clinical trial data indicated that early intervention with quercetin significantly reduced hospitalization time and the need for supplemental oxygen.

Discussion and Future Directions

This study positions senolytics as a promising class of "anti-inflammatories" that remove the source of inflammation rather than just dampening the immune response. However, challenges remain, including determining the optimal timing for intervention and managing potential drug toxicities, such as the transient thrombocytopenia associated with navitoclax.

Future research will explore whether persistent VIS cells contribute to "Long COVID" and if senolytic "clearing" can alleviate chronic post-viral symptoms. Given that VIS is a broad-spectrum response, this approach may offer a "plug-and-play" therapeutic strategy for future viral pandemics.

Summary updated

BibTeX
@inproceedings{lee2021virus,
  author = {Soyoung Lee and Yong Yu and Jakob Trimpert and Fahad Benthani and Mario Mairhofer and Paulina Richter‐Pechańska and Emanuel Wyler and Dimitri Belenki and Sabine Kaltenbrunner and Maria Pammer and Lea Kausche and Theresa C. Firsching and Kristina Dietert and Michael Schotsaert and Carles Martínez‐Romero and Gagandeep Singh and Séverine Kunz and Daniela Niemeyer and R Ghanem and Helmut J.F. Salzer and Christian Paar and Michael Mülleder and Melissa B. Uccellini and Edward Michaelis and Amjad Khan and Andrea Lau and Martin Schönlein and Anna Habringer and Josef Tomasits and Julia M. Adler and Susanne Kimeswenger and Achim D. Gruber and Wolfram Hoetzenecker and Herta Steinkellner and Bettina Purfürst and Reinhard Motz and Francesco Di Pierro and Bernd Lamprecht and Nikolaus Osterrieder and Markus Landthaler and Christian Drosten and Adolfo Garcı́a-Sastre and Rupert Langer and Markus Ralser and Roland Eils and Maurice Reimann and Dorothy Ngo-Yin Fan and Clemens A. Schmitt},
  title = {{Virus-induced senescence is a driver and therapeutic target in COVID-19}},
  booktitle = {Nature},
  year = {2021},
  doi = {10.1038/s41586-021-03995-1},
}
Figure